Corticosteroid, Osteoarthritis Knee, Platelet Rich Plasma
Conditions
Brief summary
Knee osteoarthritis is the most common type of osteoarthritis in the lower extremity and constitutes 23% of all arthritis cases, about 13% of females and 10% of males aged above 60 years have symptomatic knee OA. Intra-articular corticosteroids (IACs) are a frequently-used treatment regimen for pain relief from symptomatic knee OA as it inhibits inflammation and reduces prostaglandin synthesis. Platelet-rich plasma (PRP) is an autologous blood product containing a high percentage of various growth factors (GFs), such as fibroblast growth factor, epidermal growth factor, vascular endothelial growth factor, transforming growth factor-β and platelet-derived growth factor. The aim of this study is to compare effect of intra-articular injection of platelet rich plasma versus corticosteroid in treatment of primary knee osteoarthritis.
Interventions
DRUGCorticosteroid
The injection will be given at a site near the superolateral pole of patella in the suprapatellar pouch under aseptic conditions and the patient will be advised to take one day of rest after injection and apply ice to the area if there are any signs of inflammation.
OTHERPlatelet Rich Plasma
PRP preparation :- 20 ml of venous blood will be drawn from the antecubital vein using an 18G needle to avoid traumatizing platelets and will be collected in a sterile tube containing 2 ml of Sodium Citrate anticoagulant. Approximately 2 ml of whole blood will be separated for a complete blood count.The blood with anticoagulant will centrifuged at 4000 rpm for 6-10 minutes to separate erythrocytes and then at 4000 rpm for 6-10 min to concentrate platelets.The final product was 4-5 ml of PRP containing leukocytes with platelet concentration of 3-5 times the average normal value.
Sponsors
Benha University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Patients 40-70 years of age suffering from knee OA with Kellgren Lawrence grade II or III on standing antero-posterior and lateral knee radiographs. * Patients diagnosed according to ACR classification criteria.
Exclusion criteria
* Systemic diseases as Patients having diabetes mellitus,Cardiovascular diseases or coagulopathies. * Those receiving treatment with anticoagulant , anti\_platelet medications or systemic corticosteroid 10 days before injection or recent use of NSAIDs. * Pregnant and breast feeding females. * Patients have hemoglobin values \<10 g/dl or platelet values\<150,000/ml.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of knee pain, stiffness and physical function prior knee injection | Assessment will be done just before injection | Assessment through the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score. The final score for the WOMAC was determined by adding the aggregate scores for pain, stiffness, and function. Scores range from 0 to 96 for the total WOMAC where 0 represents the best health status and 96 the worst possible status. |
| Assessment of knee pain, stiffness and physical function 2 weeks after injection | 2 weeks after injection | Assessment through WOMAC score |
| Assessment of knee pain, stiffness and physical function 6 weeks after injection | 6 weeks after injection | Assessment through WOMAC score |
| Assessment of knee pain, stiffness and physical function 12 weeks after injection | 12 weeks after injection | Assessment through WOMAC score |
Contacts
Primary ContactArwa S. Amer, MD
Backup ContactBenha University
Outcome results
None listed